Kasper Kyhl1,2*, MD; Jacob Lønborg1, MD, PhD; Niels Vejlstrup1, MD, PhD; Henning Kelbæk1, MD, DMSc; Steffen Helqvist1, MD, DMSc; Lene Holmvang1, MD, DMSc; Erik Jørgensen1, MD; Kari Saunamäki1, MD, DMSc; Hans Erik Bøtker3, MD, PhD, DMSc; Peter Clemmensen1, MD, DMSc; Lars Køber1, MD, PhD, DMSc; Marek Treiman2, MD, DMSc; Thomas Engstrøm1, MD, PhD, DMSc
1. Department of Cardiology, Rigshospitalet, Copenhagen, Denmark; 2. Department of Biomedical Sciences, Copenhagen University, Copenhagen, Denmark; 3. Department of Cardiology, Aarhus University Hospital, Skejby, Denmark
Aims: We aimed to assess the effect of exenatide treatment as an adjunct to primary percutaneous coronary intervention (PCI) on long-term clinical outcome.